COMMUNIQUÉS West-GlobeNewswire

Genetic Technologies Strategic Restructure Driving USA Sales Growth
26/07/2024
CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent [...]
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
26/07/2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]
GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive
26/07/2024
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), 26 juillet 2024 - GENFIT (Nasdaq et Euronext : GNFT) , une société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie [...]
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
26/07/2024
TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
26/07/2024
If approved, Yuvanci ® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson’s comprehensive PAH portfolio has the potential to cover all guideline-recommended [...]
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
26/07/2024
TEL AVIV, Israel, July 26, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab) a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with [...]
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
26/07/2024
SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months [...]
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
26/07/2024
Ipsen receives CHMP positive opinions for Iqirvo ® (elafibranor) in Primary Biliary Cholangitis and Kayfanda ® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases CHMP positive opinion for Iqirvo ® ( [...]
Ipsen reçoit des avis positifs du CHMP pour Iqirvo® (elafibranor) dans la cholangite biliaire primitive et Kayfanda® (odévixibat) dans le syndrome d'Alagille, deux maladies rares du foie cholestatiques
26/07/2024
Le CHMP a émis un avis positif concernant Iqirvo ® (elafibranor) pour le traitement de la cholangite biliaire primitive, à la suite de l’approbation de la FDA en juin 2024. Le CHMP a émis un avis positif concernant [...]
Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine
26/07/2024
Real-world data demonstrating vaccine effectiveness against mpox of up to 90% after two MVA-BN doses and a significant reduction of the risk of mpox-related hospitalizations COPENHAGEN, Denmark, July 26, 2024 – Bavarian [...]
Kaerus Bioscience annonce le lancement de l’essai clinique de phase I ciblé sur son nouveau modulateur de canal BK KER-0193 en cours de développement pour le syndrome de l’X fragile
26/07/2024
LONDRES, 26 juill. 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. ( www.kaerusbio.com ), une société de biotechnologie au stade clinique axée sur le développement de traitements pour les syndromes génétiques rares [...]
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
26/07/2024
$8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage [...]
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
26/07/2024
$8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), [...]
OnKure Announces the Appointment of Dylan Hartley as Chief Scientific Officer
26/07/2024
BOULDER, Colo., July 25, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced that Dylan Hartley, Ph.D. has been appointed to the position of Chief Scientific Officer. In this position, Dr. Hartley will lead the [...]
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
25/07/2024
Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab vedotin (CAB-AXL-ADC) study; AXL tumoral expression highly associated with [...]
23andMe to Report Q1 FY2025 Financial Results
25/07/2024
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and [...]
La FDA accorde le statut de médicament orphelin et médicament pour une maladie pédiatrique rare (Rare Pediatric Disease Designation-RPDD) au produit candidat de Cellectis UCART22 pour le traitement de la leucémie lymphoblastique aiguë (LLA)
25/07/2024
o La LLA, qui représente 10% des cas de leucémie dans les États Unis, progresse rapidement, pouvant être fatale en quelques semaines ou quelques mois si elle n'est pas traitée 1 . o Il existe un besoin urgent de [...]
Travere Therapeutics to Report Second Quarter 2024 Financial Results
25/07/2024
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced it will report second quarter 2024 financial results on Thursday, August 1, 2024, after the close of the U.S. [...]
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
25/07/2024
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients [...]

Pages